Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Matos

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Neuroinflammation|June 12, 2016
Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicityShamsudheen Moidunny, Marco Matos, Evelyn Wesseling, et al.
Biological Psychiatry|April 15, 2015
Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophreniaMarco Matos, Hai-Ying Shen, Elisabete Augusto, et al.
Neurobiology of Disease|July 5, 2021
Increased ATP release and CD73-mediated adenosine A<sub>2A</sub> receptor activation mediate convulsion-associated neuronal damage and hippocampal dysfunctionElisabete Augusto, Francisco Q Gonçalves, Joana E Real, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.
Progress in Neurobiology|March 13, 2025
Astrocytic EphB3 receptors regulate d-serine-gated synaptic plasticity and memoryValentin Clément Langlais, Sarah Mountadem, Ines Benazzouz, et al.
BMJ Oncology|February 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerQing Zhou, Bo Gao, Jie Hu, et al.
Acta Neuropathologica Communications|October 17, 2018
Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer's diseaseKelly Ceyzériat, Lucile Ben Haim, Audrey Denizot, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Cell Metabolism|March 5, 2020
Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's DiseaseJuliette Le Douce, Marianne Maugard, Julien Veran, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Neuroinflammation|June 12, 2016
Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicityShamsudheen Moidunny, Marco Matos, Evelyn Wesseling, et al.
Biological Psychiatry|April 15, 2015
Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophreniaMarco Matos, Hai-Ying Shen, Elisabete Augusto, et al.
Neurobiology of Disease|July 5, 2021
Increased ATP release and CD73-mediated adenosine A<sub>2A</sub> receptor activation mediate convulsion-associated neuronal damage and hippocampal dysfunctionElisabete Augusto, Francisco Q Gonçalves, Joana E Real, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.
Progress in Neurobiology|March 13, 2025
Astrocytic EphB3 receptors regulate d-serine-gated synaptic plasticity and memoryValentin Clément Langlais, Sarah Mountadem, Ines Benazzouz, et al.
BMJ Oncology|February 25, 2026
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerQing Zhou, Bo Gao, Jie Hu, et al.
Acta Neuropathologica Communications|October 17, 2018
Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer's diseaseKelly Ceyzériat, Lucile Ben Haim, Audrey Denizot, et al.
Lancet (London, England)|January 11, 2025
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyBruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, et al.
Cell Metabolism|March 5, 2020
Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's DiseaseJuliette Le Douce, Marianne Maugard, Julien Veran, et al.
Pageof 2